Letters to the Editor

The use of hydroxyurea pretreatment in chronic myeloid leukemia in the current tyrosine kinase inhibitor era

Department of Internal Medicine, Hematology, Albert Schweitzer Hospital, Dordrecht
Department of Hematology, Erasmus University Medical Center, Rotterdam
Department of Internal Medicine, Hematology, Albert Schweitzer Hospital, Dordrecht
Department of Hematology, Amsterdam University Medical Center, location VU Medical Center, Amsterdam
Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands; Department of Public Health, Erasmus University Medical Center, Rotterdam
Department of Hematology, Medical Center Leeuwarden, Leeuwarden
Department of Hematology, Erasmus University Medical Center, Rotterdam
Department of Internal Medicine, Hematology, Albert Schweitzer Hospital, Dordrecht
Haematologica Early view Mar 31, 2022 https://doi.org/10.3324/haematol.2021.280501